Compare Cassava Sciences Inc (FLNA) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs M&T Bank Corporation — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while M&T Bank Corporation trades at $253.32 (market cap $36.02B). The key difference: M&T Bank Corporation is far larger — about 677.8× Cassava Sciences Inc's market cap, and M&T Bank Corporation pays a 2.41% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | MTB | |
|---|---|---|
Market Cap | $53.14M | $36.02B |
Sector | Health | Financials |
52-Week High | $4.64 | $248.53 |
52-Week Low | $1.09 | $178.63 |
Enterprise Value | -$33.43M | — |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
M&T Bank (MTB) trades at $253.23, up 4.71% on strong Q2 2026 earnings that beat expectations with EPS of $5.35 versus $4.66 estimates. The stock shows bullish technical momentum with price above key resistance levels, supported by solid fundamentals including a 30.11% net income margin and consistent earnings growth. Recent analyst coverage reflects cautious optimism with 29% buy ratings amid a predominantly hold consensus.
MTB presents a balanced investment case with strong profitability and dividend yield, though near-term risks include declining operating cash flow and elevated debt levels. The stock trades at a reasonable P/E of 13.16, offering value relative to earnings growth potential, but investors should monitor net interest income trends and credit quality amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
